维普期刊资源整合服务平台（V6.5）

49篇 您的检索式：作者名="TSIMIHODIMOS V"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	高血压与糖尿病:共同发展与时间轨迹研究显示文摘在人群中2型糖尿病与高血压常合并存在。许多个体糖尿病的发展特点是血浆葡萄糖值的相对快速升高。高血压的发展是否存在相似的现象仍不明确。该研究采用来自墨西哥城糖尿病研究(Mexico city diabetes study,MCDS;一个基于西班牙裔白人的糖尿病人群研究)及Framingham后代研究(Framingham offspring study,FOS;一个基于社区的非西班牙裔白人研究)的7年随访数据,分析未合并或合并糖尿病的患者高血压发展过程中的血压变化模式。	赵狄练桂丽 Tsimihodimos V Gonzalez-Villalpando C Meigs JB Ferrannini E	2018	中华高血压杂志2018，26，1：	3
2	Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetyl- hydrolase activity in dyslipidemias of type IIA and type IIB显示文摘	Tsimihodimos V Karabina SA Tambaki AP	2002	Arterioscler Thromb Vasc Biol2002，22，2：	1
3	Dyslipidemia in chronic kidney disease:an approach to pathogenesis and treatment显示文摘	Tsimihodimos V Dounousi E Siamopoulos KC	2008	Am J Nephrol2008，28，6：	1
4	Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles 显示文摘	Tsimihodimos V Gazi I Kostara C	2007	Lipids2007，42，5：	1
5	Altera- tion in the high density lipoprotein phenotype and HDL as- sociated enzymes in subjects with metabolic syndrome 显示文摘	Lagos K G Filippatos T D Tsimihodimos V	2009	Lipids2009，44，1：	1
6	Increased plas- ma visfatin concentration is a marker of an atherogenic metabolic profile 显示文摘	Filippatos T D Tsimihodimos V Derdemezis C S	2013	Nutr Metab Cardiovasc Dis2013，23，4：	1
7	High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia显示文摘	Agouridis AP Tsimihodimos V Filippatos TD	2011	Lipids2011，46，6：	1
8	Plasma lipoproteins and tri- acylglycerol are predictors of small, dense LDL particles 显示文摘	Tsimihodimos V Gazi I Kostara C	2007	Lipids2007，42，5：	1
9	Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-eontaining lipoproteins 显示文摘	Tsimihodimos V Kakafika A Tambaki AP	2003	J Lipid Res2003，44，5：	1
10	Prediabetes: to treat or not to treat? 显示文摘	Moutzourl E Tsimihodimos V Rizos E	2011	Eur J Pharmaeol2011，672，13：	1
11	Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile 显示文摘	FILIPPATOS TD TSIMIHODIMOS V DERDEMEZIS CS etal	2013	Nutr Metab Cardiovasc Dis2013，23，4：	1
12	Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particle 显示文摘	Tsimihodimos V Gazi I Kostara C	2007	Lipids2007，42，5：	1
13	Fenofibrate: metabolic and pleiotropic effects 显示文摘	Tsimihodimos V Miltiadous G Daskalopoulou SS	2005	Curr Vasc Pharmacol2005，3，1：	1
14	Plasma lipoproteins and triacylglycerol are predictors of small,dense LDL particle显示文摘	Tsimihodimos V Gazi I Kostara C		0，，：	1
15	Effect of atorvastatin on serum uric acid levels显示文摘	Kakafika A Tsimihodimos V Elisaf M	2001	Atherosclerosis2001，158，1：	1
16	Pleiotropic effects of ezetimibe:do they really exist?显示文摘	KALOGIROU M TSIMIHODIMOS V ELISAF M	2010	Eur J Pharmacol2010，633，123：	1
17	Plasma triglyeeride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia 显示文摘	Tsimihodimos V Gazi I Filippatos T	2010	Atheroselerosis2010，208，2：	1
18	Fenobriates induces HDL-associated PAF-acetylhydrolase but attenuates enzyme activity assciated with apo-B containing lipoproteins 显示文摘	Tsimihodimos V Kakafika A Afroditi P	2003	J Lipid Res2003，44，：	1
19	A-nalysis of 6-month effect of orlistat administration,aloneor incombination with fenofibrate,on triglyceride-rich lip-oprotein metabolism in overweight and obese patients withmetabolic syndrome显示文摘	Filippatos TD Tsimihodimos V Kostapanos M	2008	J Clin Lipidol2008，2，4：	1
20	显示文摘	Tsimihodimos V Karabina SA Tambaki AP	2002	Arterioscler Thromb Vasc Biol2002，22，：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示